Cost-Effectiveness Analysis of Abemaciclib Plus Fulvestrant in the Second-Line Treatment of Women With HR+/HER2– Advanced or Metastatic Breast Cancer: A US Payer Perspective
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cost-Effectiveness Analysis of Abemaciclib Plus Fulvestrant in the Second-Line Treatment of Women With HR+/HER2– Advanced or Metastatic Breast Cancer: A US Payer Perspective
Authors
Keywords
-
Journal
Frontiers in Medicine
Volume 8, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-06-02
DOI
10.3389/fmed.2021.658747
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Overall survival of CDK4/6-inhibitors-based treatments in clinically relevant subgroups of metastatic breast cancer: systematic review and meta-analysis
- (2020) Francesco Schettini et al. JNCI-Journal of the National Cancer Institute
- Predicting future cancer burden in the United States by artificial neural networks
- (2020) Francesco Piva et al. Future Oncology
- Cost-Effectiveness of Ribociclib for Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
- (2020) Jiangping Yang et al. Cancer Management and Research
- Cost-Effectiveness Analysis of Adding Palbociclib as a Second-Line Endocrine Therapy for HR+/HER2– Metastatic Breast Cancer From the US and Chinese Perspectives
- (2019) Yingjie Zhang et al. CLINICAL THERAPEUTICS
- The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
- (2019) George W. Sledge et al. JAMA Oncology
- Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis
- (2019) Mario Giuliano et al. LANCET ONCOLOGY
- Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
- (2019) Dennis J. Slamon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Economic Burden of HR+/HER2- Metastatic Breast Cancer Among Adult Premenopausal Women
- (2018) Geneviève Gauthier et al. ADVANCES IN THERAPY
- Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3
- (2018) Dennis J. Slamon et al. JOURNAL OF CLINICAL ONCOLOGY
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective
- (2018) Rohit Mistry et al. Journal of Managed Care & Specialty Pharmacy
- Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
- (2018) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
- (2017) George W. Sledge et al. JOURNAL OF CLINICAL ONCOLOGY
- Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States
- (2017) Anna Oh et al. Journal of Managed Care & Specialty Pharmacy
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
- (2016) Massimo Cristofanilli et al. LANCET ONCOLOGY
- Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors
- (2016) A. Patnaik et al. Cancer Discovery
- A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada
- (2016) C. Beauchemin et al. JOURNAL OF MEDICAL ECONOMICS
- ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
- (2014) F. Cardoso et al. BREAST
- US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
- (2014) Nadia Howlader et al. JNCI-Journal of the National Cancer Institute
- Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold
- (2014) Peter J. Neumann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Patterns of treatment, healthcare utilization and costs by lines of therapy in metastatic breast cancer in a large insured US population
- (2013) Saurabh Ray et al. Journal of Comparative Effectiveness Research
- Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves
- (2012) Patricia Guyot et al. BMC Medical Research Methodology
- Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy
- (2012) Amye J. Tevaarwerk et al. CANCER
- INCIDENCE-BASED COST-OF-ILLNESS MODEL FOR METASTATIC BREAST CANCER IN THE UNITED STATES
- (2012) Sonja V. Sorensen et al. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE
- Projections of the Cost of Cancer Care in the United States: 2010-2020
- (2011) A. B. Mariotto et al. JNCI-Journal of the National Cancer Institute
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started